Mobile

A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibrosis ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-000995-41

A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To describe the safety and efficacy of two doses of GI262570 treatment in chronic hepatitis C subjects with Genotype 1 infection, who have failed prior anti-HCV therapy, in improving immunohistochemical markers of fibrogenesis (markers of HSC activation) over the course of the study as compared with placebo-treated subjects

Critère d'inclusion

  • Chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy

Liens